In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest pays $240mm up front for exclusive US rights to Merck's Saphris

Executive Summary

Spec pharma Forest Laboratories Inc. (CNS, cardiovascular, GI, respiratory, and infectious disease therapies) paid $240mm up front for exclusive US rights to Merck & Co. Inc.’s antipsychotic drug Saphris (asenapine). Forest could also pay undisclosed sales milestones.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies